AT

Andy Tran

Principal at Matrix Capital Management | Biotech Investor | Board Director

Greater Boston

VC
Investor

Invests in

  • Min Investment:

    $100,000.00

  • Max Investment:

    $10,000,000.00

  • Target Investment:

    $1,000,000.00

Skills

Molecular Biology
Biomedical Engineering
Clinical Research
Medical Devices
Biotechnology
Genetic Engineering
C
Genome Sequencing
Computational Biology
Entrepreneurship
Java
Immunoassays
Computational Genomics
Matlab
Computer Hardware
C++
Python
Nanomedicine
Cloud Computing
PCR

Education

Investments

Maze Therapeutics

Series Unknown

Total Funding: $380M

GentiBio

Series A

Total Funding: $160M

Work Experience

ReCode Therapeutics

2022

  • Board Observer and Investor

    2022

Maze Therapeutics

2022

  • Board Director and Lead Investor

    2022

GentiBio

2021

  • Board Director and Lead Investor

    2021

Matrix Capital Management Company, L.P.

2021

  • Principal

    2021

    Leading investments in innovative biotechnology and healthcare companies. Focusing on long term investing out of a $8Bn AUM hedge fund to support companies through their entire life cycle (from early through crossover and public stages).

Andreessen Horowitz

2018 - 2021

  • Investment Partner

    2018 - 2021

    Investing in early stage ventures at the frontier of biotech and engineering in therapeutics, diagnostics and tools. Seed and Series A Lead investments include Scribe Therapeutics, Insitro, Genesis Therapeutics, EQRx, Octant Biosciences, Tmunity, Nautilus, Earli, and several stealth seeds in the biotech space.

Scribe Therapeutics

2018 - 2021

  • Investor and Board Observer

    2018 - 2021

Asimov

2018 - 2021

  • Board Observer

    2018 - 2021

insitro

2018 - 2021

  • Investor

    2018 - 2021

EQRx

2018 - 2021

  • Investor

    2018 - 2021

Freenome

2018 - 2021

  • Board Observer

    2018 - 2021